Correction to: International Journal of Hematology https://doi.org/10.1007/s12185-022-03349-1

In the original publication of the article, the table related to case study was missing. The case study table is given in this correction.

Case

Disease

CD20 MoAb*1

SARS-CoV2

Anti-SARS-CoV-2 Antibodies (AU/mL)*2

Serum IgG (mg/dL)*3

Time*4

Infection

Vaccine

IgG-N

IgM-N

IgG-S1

IgM-S1

Nab

Case 1

FL

37

+

−

n.t.*5

n.t

n.t

n.t

0.68

563

 + 2w

     

0.27

0.14

0.39

0.21

3.48

441

 + 4w

     

0.19

0.33

0.37

0.23

1.44

183

 + 10w

Case 2

FL

1

+

−

9.46

0.82

0.47

0.48

2.37

685

 + 2w

     

235.22

29.82

16.79

2.23

21.21

576

 + 4w

Case 3

FL

12

+

+

0.32

1.12

7.09

594.44

140.16

492

 + 2w

     

0.32

0.95

8.01

578.75

213.00

461

 + 4w

Case 4

Healthy

0

−

+

0.53

0.16

9.78

0.63

5.88

1,290

 + 2w

     

0.50

0.17

2145.96

18.97

2836.82

1,291

 + 4w

*1: Number of anti-CD20 monoclonal antibody-containing chemotherapy sessions administered in each case

*2: Bold numbers with underline mean positive antibody titers (> 10 AU/mL)

*3: Reference interval of serum IgG is 861–1747 mg/dL in our hospital

*4: In Cases 1–3, time from the onset of SARS-CoV2 infection. In Case 4, time from the initial vaccination

*5: n.t.: not tested